J.W. Cole Advisors, Inc. Acadia Pharmaceuticals Inc Transaction History
J.W. Cole Advisors, Inc.
- $2.42 Billion
- Q4 2024
A detailed history of J.W. Cole Advisors, Inc. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, J.W. Cole Advisors, Inc. holds 17,620 shares of ACAD stock, worth $353,104. This represents 0.01% of its overall portfolio holdings.
Number of Shares
17,620
Previous 17,620
-0.0%
Holding current value
$353,104
Previous $271,000
19.19%
% of portfolio
0.01%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding ACAD
# of Institutions
306Shares Held
157MCall Options Held
828KPut Options Held
317K-
Baker Bros. Advisors LP New York, NY42.9MShares$859 Million8.72% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.9MShares$280 Million0.0% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$242 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY8.71MShares$174 Million2.61% of portfolio
-
Morgan Stanley New York, NY7.3MShares$146 Million0.01% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $3.24B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...